正海生物 reported revenue of ¥0.16B for the period ended 2026-06-30, -14.9% year on year. Net income was ¥0.03B, a 20.8% net margin on a 82.4% gross margin. The largest revenue line is 脑膜系列产品 at 43% of the total. Free cash flow for the period was ¥0.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.16B | -14.9% |
| Gross profit | ¥0.13B | — |
| Operating income | ¥0.04B | — |
| Net income | ¥0.03B | -27.9% |
| Gross margin | 82.4% | Net margin 20.8% |
| Revenue Q/Q | -2.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 脑膜系列产品 | ¥0.07B | 43.5% |
| 口腔修复膜 | ¥0.06B | 36.2% |
| 其他主营业务 | ¥0.03B | 19.9% |
| 其他(补充) | ¥0.00B | 0.5% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.03B | 17.6% |
| R&D | ¥0.02B | 15.0% |
| SG&A | ¥0.07B | 46.4% |
| Tax & other | ¥0.00B | 2.1% |
| Item | Amount |
|---|---|
| Total assets | ¥0.97B |
| Total liabilities | ¥0.10B |
| Shareholders' equity | ¥0.87B |
| Equity / assets | 90.0% |
| Operating cash flow | ¥0.02B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.01B |
| Cash conversion (OCF / net income) | 85% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
世纪天鸿 ・ 晶瑞电材 ・ 民德电子 ・ 弘信电子 ・ 延江股份 ・ 中孚信息 ・ 江苏雷利 ・ 科锐国际 ・ 科蓝软件 ・ 鹏鹞环保 ・ 飞鹿股份 ・ 江丰电子
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies